EGFR mutations in Latinos from the United States and Latin America.

dc.contributor.authorAriel López-Chávez
dc.contributor.authorMoses O. Evbuomwan
dc.contributor.authorLiqiang Xi
dc.contributor.authorGuinevere Chun
dc.contributor.authorTatiana Vidaurre
dc.contributor.authorÓscar Arrieta
dc.contributor.authorGeorge Oblitas
dc.contributor.authorAna B. Oton
dc.contributor.authorAlejandro Calvo
dc.contributor.authorArun Rajan
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T15:13:17Z
dc.date.available2026-03-22T15:13:17Z
dc.date.issued2015
dc.descriptionCitaciones: 4
dc.description.abstract8070 Background: Activating mutations in the epidermal growth factor receptor gene (EGFR) confer hypersensitivity to EGFR tyrosine kinase inhibitors in patients with advanced non–small-cell lung cancer (NSCLC). Racial and ethnic differences in the frequency of such mutations have been previously described; however, there are limited and conflicting reports on its frequency in the Latino population. Methods: We collected samples from 642 patients with NSCLC from 7 institutions in the US and Latin-America. Activating EGFR mutation analysis of exons 18 through 21 was performed at 2 CLIA certified central laboratories. Statistical analyses were performed using Fisher’s exact test or Mehta’s modification to Fisher’s exact test to determine relationships among parameters. All p-values are two-tailed and reported without adjustment for multiple comparisons. Results: EGFR mutation analysis was successfully performed in 480 of 642 patients (75%) of which 90 (19%) were Latinos, 318 (66%) non-Latino Whites, 35 (7%) non-Latino Asians, 30 (6%) non-Latino Blacks and 7 (2%) from other race/ethnicities. EGFR mutations were found in 21 of 90 (23%) Latino patients and its frequency varied according to country of origin. The highest frequency was observed in Latinos from Peru (37%) followed by US (23%), Mexico (18%), Venezuela (10%) and Bolivia (8%). In Latinos never smokers and Latinos with adenocarcinoma histology, the frequency of EGFR mutations was 38% and 30% respectively. There was a significant difference in the frequency of EGFR mutations among the different racial/ethnic subgroups analyzed (p < 0.001) with non-Latino Asians having the highest frequency (57%) followed by Latinos (23%), non-Latino Whites (19%) and non-Latino Blacks (10%). However, there was no difference between Latinos (23%) and non-Latinos (22%) (p = 0.78) and Latinos and non-Latino Whites (p = 0.37). While patients from Peru had an overall higher frequency of mutations (37%) than all other Latinos (17%), such difference was not statistically significant (p = 0.06) and diminished greatly when smoking and adenocarcinoma histology subgroups were analyzed independently. Conclusions: There was no significant difference between the frequency of EGFR mutations in NSCLC in Latinos and non-Latinos.
dc.identifier.doi10.1200/jco.2015.33.15_suppl.8070
dc.identifier.urihttps://doi.org/10.1200/jco.2015.33.15_suppl.8070
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/51093
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofJournal of Clinical Oncology
dc.sourceSylvester Comprehensive Cancer Center
dc.subjectMedicine
dc.subjectExact test
dc.subjectLung cancer
dc.subjectInternal medicine
dc.subjectDemography
dc.subjectPopulation
dc.subjectEpidermal growth factor receptor
dc.subjectEthnic group
dc.subjectLatin Americans
dc.subjectOncology
dc.titleEGFR mutations in Latinos from the United States and Latin America.
dc.typearticle

Files